Eurofins Scientific SEERFSF +2.60%81 PE Ratio without NRI is 16.86 as of Jun. 24, 2026, which is 17% below its 10-year median of 20.41. GuruFocus rates ERFSF with a GF Score™ of 81/100 and a GF Value™ of $76.00 (Fairly Valued). The stock has 6 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks better than 78.57% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-24), Eurofins Scientific SE's share price is $76.03.
Eurofins Scientific SE's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $4.51. Therefore, Eurofins Scientific SE's PE Ratio without NRI for today is 16.86.
During the past 13 years, Eurofins Scientific SE's highest PE Ratio without NRI was 43.95. The lowest was 12.03. And the median was 20.41.
Eurofins Scientific SE (OTCPK:ERFSF) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Eurofins Scientific SE PE Ratio without NRI Related Terms
Eurofins Scientific SE PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Eurofins Scientific SE's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ERFSF vs TMO, DHR, IDXX: PE Ratio without NRI Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's PE Ratio without NRI falls into.
Eurofins Scientific SE PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Eurofins Scientific SE's Share Price of today is $76.03.
For company reported semi-annually, Eurofins Scientific SE's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.51.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Eurofins Scientific SE (ERFSF) has a PE Ratio without NRI of 16.86 as of Jun. 24, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Eurofins Scientific SE and its competitors. This is 17% below median its historical median of 20.41. Over the past decade, Eurofins Scientific SE's PE Ratio without NRI has ranged from 12.03 to 43.95. According to the industry distribution chart, Eurofins Scientific SE ranks #21 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 21.4%.
Is Eurofins Scientific SE's PE Ratio without NRI too high?
Eurofins Scientific SE's current PE Ratio without NRI of 16.86 is 17% below median its 10-year median of 20.41. Over the past 10 years, this metric has ranged from a low of 12.03 to a high of 43.95. The Medical Diagnostics & Research industry median PE Ratio without NRI is 27.19. Eurofins Scientific SE's value of 16.86 is 38% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #21 out of 98 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's PE Ratio without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #21 out of 98 companies for PE Ratio without NRI. This places Eurofins Scientific SE in the top 21% of its industry — outperforming the majority of peers. The industry median PE Ratio without NRI is 27.19. Eurofins Scientific SE's value of 16.86 is 38% below this benchmark. Historically, Eurofins Scientific SE's own PE Ratio without NRI has ranged from 12.03 to 43.95 over the past decade. While the company's 10-year median is 20.41 vs. the industry median of 27.19, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Diagnostics & Research company?
The median PE Ratio without NRI among Medical Diagnostics & Research companies is 27.19, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current PE Ratio without NRI of 16.86 is 38% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio without NRI is 27.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current PE Ratio without NRI is 16.86, which is 17% below median its own 10-year median of 20.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $76.00, compared to a current price of $76.03 — trading 0% above its estimated fair value. The current PE Ratio without NRI is 16.86, which is 17% below median its 10-year median of 20.41 and 38% below the Medical Diagnostics & Research industry median of 27.19. Eurofins Scientific SE's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current PE Ratio without NRI is 16.86 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $76.03 is trading 0% above its estimated GF Value™ of $76.00.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
PE Ratio without NRI: 16.86 (17% below median its 10-year median of 20.41)
GF Value™: $76.00 vs. price of $76.03 (0% above fair value)
Industry Position: 38% below the Medical Diagnostics & Research median (#21 of 98)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
81GF Score
Get the complete analysis for ERFSF
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
